OUR STORY A Mission to Improve Patient Comfort A Need for Less Painful, Faster-Acting Dental Injections Dr. Scott Keadle, a dentist for over 30 years, experienced firsthand the limitations of current dental anesthetic drugs and their inability to provide a fast-acting, reliable, and painless injection. He wanted a better anesthetic for his patients: Less injection pain, less waiting time, and more reliability. A New Anesthetic. Created for Dentists, by Dentists. Dr. Keadle invented patented technology to enable pH-balanced versions of the most common local anesthetics, using a standard syringe and protocol. He then presented the opportunity to a group of dentists who invested over $1 million to help found Balanced Pharma Incorporated (BPI). . Now he leads a team of industry experts who are committed to bringing the first-ever pH-balanced dental anesthetic to market. 1 2 SDM Northcoast report, “Injectable Carpules Market Size Analysis, United States, Canada, Mexico, 2019 Units”, July 15, 2021; BPI owns the following granted patents and pending patent applications: U.S. Patent No. 11,305,064 (issued April 19th, 2022); U.S. Application No. 17/722,016; International PCT Application No. PCT/IB2018/052598; Canadian Application No. 3,111,347 (Canadian National Phase of PCT/IB2018/052598); European Application No. 18897951.2 (European Regional Phase of PCT/IB2018/052598); Japanese Application No. 2020-556351 (Japanese National Phase of PCT/IB2018/052598); Korean Application No. 10-2020-7021685 (Republic of Korea National Phase of PCT/IB2018/052598); U.S. Application No. 16/655,362; U.S. Application No. 63/233,879; BPI also owns one trademark application, U.S. Application No. 88/198,808, pending for the LIBRACAINE mark. Balanced Pharma products have not been approved by FDA and are not available for sale. PRIVATE & CONFIDENTIAL